US Food and Drug Administration (FDA)

SmartHeart can cut the number of required breath-holds for basic views by up to 75%, making the examination considerably more comfortable for those being scanned.

Abbott engineered the HERO reader to be 60% lighter than its predecessor, making it practical for daily use and convenient enough for patients to carry during travel.

The newly cleared system allows clinicians to mechanically loosen and remove debris and microorganisms from wounds during powered irrigation procedures.

The new generic formulation matches the composition of Celgene’s original Pomalyst medication and comes in four different strengths: 1mg, 2mg, 3mg, and 4mg.

The U.S. Food and Drug Administration (FDA) recently approves an updated label for UNLOXCYT based on long-term follow-up data from the pivotal CK-301-101 clinical trial.

The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.

The Bendit17 microcatheter incorporates Bendit’s proprietary real-time 3D steering technology, which enables clinicians to maneuver the device more intuitively through complex vascular pathways.

Waskyra is specifically indicated for pediatric patients aged six months and older, as well as adults diagnosed with WAS who have a mutation in the WAS gene.

The newly approved toolbox serves as a sophisticated aid for healthcare professionals who need to identify signs of acute deterioration in their inpatient populations.

The test distinguishes between three distinct Bordetella species that cause different types of illness: B. pertussis, B. parapertussis and B. holmesii